Trump’s Rescheduling Order and $265M Cash Cushion Shape Tilray’s Q2 Outlook
Tilray reports Q2 2026 results on Jan. 8 with consensus EPS loss of $0.20 on $211 million revenue. President Trump’s order to reschedule cannabis to Schedule III may eliminate the Section 280E tax burden, and Tilray, with $265 million cash, launched its Medical USA unit to capitalize on the change.
1. Analyst Sentiment Strengthens on Price Target Upside
Over the past year, Tilray Brands has seen its consensus price target more than double, rising from $4.50 to $10.00. This shift reflects heightened optimism driven by anticipated regulatory changes in the U.S. cannabis market. Notably, CIBC analyst John Zamparo maintains a more conservative target of $8.00, emphasizing caution ahead of Tilray’s second-quarter earnings release on January 8, 2025. The divergence among analysts underscores both the opportunity and the uncertainty tied to cannabis reclassification and market expansion.
2. Q2 Earnings Preview Highlights Path to Profitability
For the quarter ending December 31, Tilray is forecast to report an adjusted loss per share of $0.20 and revenue of $210.95 million, roughly flat year-over-year. While the projected revenue aligns closely with consensus estimates, the marked improvement in EPS—from a $1.00 loss a year ago to $0.20—signals progress toward breakeven. Investors will scrutinize management’s commentary on margin recovery in the beverage alcohol segment and the ongoing performance of wellness products.
3. Balance Sheet Strength and Cash Deployment
Tilray enters the new fiscal year with a conservative debt-to-equity ratio of 0.15 and a robust current ratio of 2.62, indicating ample liquidity and cautious leverage. The company reported $265 million in cash on hand as of its last quarterly filing. A significant portion of this cash is earmarked for U.S. infrastructure investment—particularly the buildout of Tilray Medical USA facilities—and for bolstering working capital should Section 280E tax relief materialize under upcoming policy shifts.
4. Strategic Initiatives Driving Long-Term Growth
Tilray continues to diversify its product portfolio with GMP-certified flowers, oils, vapes, edibles and topicals, aiming to capture broader consumer demand. The launch of Tilray Medical USA in December positions the company to capitalize on potential Schedule III rescheduling of cannabis, which could unlock millions in annual cash flow by eliminating punitive tax treatments. Meanwhile, strategic partnerships in the beverage alcohol and wellness sectors are expected to drive incremental revenue and enhance Tilray’s competitive positioning in key markets.